Positron Emission Tomography in oncology: present and future of PET and PET/CT.

PET is a crucial technique in molecular imaging, allowing in vivo assessment and localization of pathological processes, thanks to its ability to detect very small amounts of radioactive molecules. This is of particular interest in oncology where abnormal metabolism or synthesis in tumor cells but also various tumor characteristics can be studied using this nuclear medicine technique. FDG is currently the most widely used tracer, nowadays essential in the management of various malignancies, with large applications in diagnosis, initial assessment, therapy monitoring, and recurrence detection. The combination of anatomical information provided by PET/CT further increased its interest. Beyond its spread use in daily practice, future applications of PET will involve other tracers than FDG and develop research applications in humans as well as in small animals.

[1]  W. Schima,et al.  Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. , 2009, European journal of radiology.

[2]  D. Matchar,et al.  Meta‐analysis: the detection of pancreatic malignancy with positron emission tomography , 2004, Alimentary pharmacology & therapeutics.

[3]  J. Mortensen,et al.  The Future in Diagnosis and Staging of Lung Cancer: Positron Emission Tomography , 2006, Respiration.

[4]  R. Delgado-Bolton,et al.  Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  C. Wiele,et al.  Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Blaufox,et al.  A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma , 2005, Cancer.

[7]  E Yorke,et al.  Four-dimensional (4D) PET/CT imaging of the thorax. , 2004, Medical physics.

[8]  Jingli Wang,et al.  Positron Emission Tomography: applications in drug discovery and drug development. , 2005, Current topics in medicinal chemistry.

[9]  Lavanya Sundararajan,et al.  18 F-Fluoroestradiol , 2007 .

[10]  H. Herschman Noninvasive imaging of reporter gene expression in living subjects. , 2004, Advances in cancer research.

[11]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[12]  Patrice Jichlinski,et al.  Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  F. Alongi,et al.  Combining Independent Studies of Diagnostic Fluorodeoxyglucose Positron-Emission Tomography and Computed Tomography in Mediastinal Lymph Node Staging for Non-Small Cell Lung Cancer , 2006, Tumori.

[14]  I. Bradbury,et al.  Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. , 2007, Health technology assessment.

[15]  H. Groen,et al.  Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Martin,et al.  PET and PET-CT for evaluation of colorectal carcinoma. , 2004, Seminars in nuclear medicine.

[17]  R. Hustinx,et al.  Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  D. Schuster,et al.  Gastrointestinal tract malignancies and positron emission tomography: an overview. , 2006, Seminars in nuclear medicine.

[19]  J. Steinbach,et al.  Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Hubert Vesselle,et al.  FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. , 2007, Seminars in nuclear medicine.

[21]  S. Gambhir,et al.  A review of the literature for whole-body FDG PET in the management of patients with melanoma. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[22]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Julie Sutcliffe-Goulden,et al.  Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Suman Jana,et al.  Nuclear medicine studies of the prostate, testes, and bladder. , 2006, Seminars in nuclear medicine.

[25]  Arion F Chatziioannou,et al.  Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. , 2005, Proceedings of the American Thoracic Society.

[26]  A. Zwinderman,et al.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. , 2005, Radiology.

[27]  D. Owens,et al.  Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer , 2003, Annals of Internal Medicine.

[28]  G. Hanks,et al.  Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. , 2001, Seminars in radiation oncology.

[29]  Gang Huang,et al.  CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. , 2009, European journal of radiology.

[30]  C. McConkey,et al.  A systematic review and meta‐analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy , 2008, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[31]  M. Schwaiger,et al.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Blaufox,et al.  A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases , 2005, Breast Cancer Research and Treatment.

[33]  Wolfgang A Weber,et al.  Monitoring cancer treatment with PET/CT: does it make a difference? , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[35]  Jean-Claude Liehn,et al.  Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Richard P Baum,et al.  Imaging of neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[37]  B. S. Yurrita,et al.  [Systematic review and meta-analysis of diagnostic accuracy of 18F-FDG PET in suspected recurrent head and neck cancer]. , 2008 .

[38]  Wei Chen,et al.  Advances in evaluation of primary brain tumors. , 2008, Seminars in nuclear medicine.

[39]  Cyrill Burger,et al.  PET-CT image co-registration in the thorax: influence of respiration , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  Thomas Beyer,et al.  X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. , 2003, Seminars in nuclear medicine.

[41]  R. Coleman,et al.  Is quantitation necessary for oncological PET studies? , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[43]  Karin Haustermans,et al.  PET-based treatment planning in radiotherapy: a new standard? , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  Wei Chen Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.

[45]  Elliot R McVeigh,et al.  Emerging imaging techniques. , 2006, Circulation research.

[46]  T. Yen,et al.  Positron emission tomography in gynecologic cancer. , 2006, Seminars in nuclear medicine.

[47]  A. Jackson,et al.  Metabolic and molecular imaging in neuro-oncology , 2007, The Lancet Neurology.

[48]  Mithat Gönen,et al.  Screening for cancer with PET and PET/CT: potential and limitations. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  U Ruotsalainen,et al.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  Ora Israel,et al.  Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  J. Mortensen,et al.  Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. , 2001, The Lancet. Oncology.

[52]  M. Mathews,et al.  A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[53]  M. M. Mac Manus,et al.  PET scanning in lung cancer: current status and future directions. , 2003, Seminars in surgical oncology.

[54]  E. Touboul,et al.  La TEP dans les tumeurs malignes cérébrales , 2006 .

[55]  Heinrich R Schelbert,et al.  Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  J. Thie Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  A. Scott,et al.  Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. , 2007, Seminars in nuclear medicine.

[58]  J. Mackey,et al.  The role of 2‐deoxy‐2‐[F‐18]fluoro‐D‐glucose positron emission tomography in disseminated carcinoma of unknown primary site , 2007, Cancer.

[59]  J. Mercer Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[60]  Adriano Duatti,et al.  In vivo imaging of oligonucleotides with nuclear tomography. , 2004, Current drug targets.

[61]  Y. Guan,et al.  Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. , 2007, World journal of gastroenterology.

[62]  S R Cherry,et al.  A microPET/CT system for in vivo small animal imaging. , 2007, Physics in medicine and biology.

[63]  W. Oyen,et al.  The Role of FDG-PET in the Selection of Patients with Colorectal Liver Metastases , 2007, Annals of Surgical Oncology.

[64]  Weibo Cai,et al.  Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.

[65]  [2002 Standards, Options and Recommendations for the use of [18F]-FDG (PET-FDG) in cancerology]. , 2003, Bulletin du cancer.

[66]  Roland Bares,et al.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[67]  L. Mortelmans,et al.  Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. , 2006, Anticancer research.

[68]  H. Wester,et al.  Nuclear Imaging Probes: from Bench to Bedside , 2007, Clinical Cancer Research.

[69]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[70]  Peter H Ahn,et al.  Positron emission tomography/computed tomography for target delineation in head and neck cancers. , 2008, Seminars in nuclear medicine.

[71]  J. Ioannidis,et al.  18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  M. Kaplan,et al.  Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[74]  Annick D. Van den Abbeele,et al.  The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging , 2008 .

[75]  J. Schellens,et al.  Application of PET/CT in the development of novel anticancer drugs. , 2008, The oncologist.

[76]  Xiaoyi Jiang,et al.  Lung motion correction on respiratory gated 3-D PET/CT images , 2006, IEEE Transactions on Medical Imaging.

[77]  Eyal Mishani,et al.  18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. , 2007, Seminars in nuclear medicine.

[78]  M. Alber,et al.  Imaging oxygenation of human tumours , 2006, European Radiology.

[79]  R L Wahl,et al.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.

[80]  O. Warburg Über den Stoffwechsel der Carcinomzelle , 1924, Naturwissenschaften.

[81]  Pat Zanzonico,et al.  Positron emission tomography: a review of basic principles, scanner design and performance, and current systems. , 2004, Seminars in nuclear medicine.

[82]  A. Groves,et al.  The role of positron emission tomography in the management of pancreatic cancer. , 2006, Seminars in nuclear medicine.

[83]  M. M. Mac Manus,et al.  Initial staging of lymphoma with positron emission tomography and computed tomography. , 2005, Seminars in nuclear medicine.

[84]  S. Larson,et al.  Peritoneal carcinomatosis: role of (18)F-FDG PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[85]  T. DeGrado,et al.  Cancer imaging with fluorine-18-labeled choline derivatives. , 2007, Seminars in nuclear medicine.

[86]  R. Hustinx,et al.  Evaluation of therapy for lymphoma. , 2005, Seminars in nuclear medicine.

[87]  L. Bonomo,et al.  Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls , 2009, Abdominal Imaging.

[88]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  R. Wahl,et al.  Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  Lotty Hooft,et al.  18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.

[91]  S Fanti,et al.  Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[92]  S. Gambhir,et al.  MicroPET imaging of prostate cancer in LNCAP‐SR39TK‐GFP mouse xenografts , 2003, The Prostate.

[93]  C. Meltzer,et al.  PET/CT: form and function. , 2007, Radiology.

[94]  S. Nehmeh,et al.  Respiratory motion in positron emission tomography/computed tomography: a review. , 2008, Seminars in nuclear medicine.

[95]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[96]  V. Ambrosini,et al.  PET in genitourinary tract cancers. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[97]  Dalton A Anjos,et al.  18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer , 2007, Journal of Nuclear Medicine.

[98]  W. Oyen,et al.  PET/CT: panacea, redundancy, or something in between? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  D. Abbott,et al.  Functional imaging of intratumoral hypoxia. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[100]  S S Gambhir,et al.  A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[101]  R. Wahl,et al.  Clinical use of positron emission tomography in the management of cutaneous melanoma. , 2004, Seminars in nuclear medicine.

[102]  J. Keyes SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  D. Hellwig,et al.  [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. , 2001, Pneumologie.

[105]  Heiko Schöder,et al.  Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. , 2008, Seminars in nuclear medicine.

[106]  R Myers,et al.  The biological application of small animal PET imaging. , 2001, Nuclear medicine and biology.

[107]  D. Papathanassiou,et al.  High-Grade Lymphoma of the Bladder Visualized on PET , 2005, Clinical nuclear medicine.

[108]  Shankar Vallabhajosula,et al.  (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. , 2007, Seminars in nuclear medicine.

[109]  Arion F. Chatziioannou,et al.  Molecular imaging of small animals with dedicated PET tomographs , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[110]  J. S. Lee,et al.  Performance Measurement of the microPET Focus 120 Scanner , 2007, Journal of Nuclear Medicine.

[111]  Kyle E. Rusthoven,et al.  The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor , 2004, Cancer.

[112]  V. Ambrosini,et al.  Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET , 2007, Nuclear medicine communications.

[113]  J. Ioannidis,et al.  18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  R. Wahl,et al.  Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. , 2003, Cancer research.

[115]  J. Chou,et al.  Cellular Release of [18F]2-Fluoro-2-deoxyglucose as a Function of the Glucose-6-phosphatase Enzyme System* , 2000, The Journal of Biological Chemistry.

[116]  Stefano Fanti,et al.  Role of small animal PET for molecular imaging in pre-clinical studies , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[117]  David Azria,et al.  Metabolic functional imaging for tumor radiosensitivity monitoring. , 2007, Critical reviews in oncology/hematology.

[118]  W Vaalburg,et al.  The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. , 2004, Cancer treatment reviews.

[119]  Wen Xu,et al.  FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[120]  T. Stijnen,et al.  Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. , 2005, The Annals of thoracic surgery.

[121]  K. Bouchelouche,et al.  Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. , 2008, The Journal of urology.

[122]  Wei Chen,et al.  Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors , 2007 .

[123]  G. Antoch,et al.  Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[124]  N. Avril,et al.  Molecular positron emission tomography and PET/CT imaging in urological malignancies. , 2007, European urology.

[125]  Matthias Reimold,et al.  18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[126]  S. Kalnicki,et al.  Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume. , 2008, Seminars in nuclear medicine.

[127]  R. C. Hawkes,et al.  Development of a Combined microPET®-MR System , 2006, 2006 IEEE Nuclear Science Symposium Conference Record.

[128]  Thomas Beyer,et al.  PET/CT scanners: a hardware approach to image fusion. , 2003, Seminars in nuclear medicine.

[129]  L. Hooft,et al.  Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[130]  Guido Slegers,et al.  Apoptosis-detecting radioligands: current state of the art and future perspectives , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[131]  Chia-Lin Chen,et al.  Merging molecular and anatomical information: A feasibility study on rodents using microPET and MRI , 2007, Nuclear medicine communications.

[132]  Peter Oehr,et al.  Recent developments in urologic oncology: positron emission tomography molecular imaging , 2008, Current opinion in oncology.

[133]  H. Shimada,et al.  Value of 18F-FDG PET in the detection of peritoneal carcinomatosis , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[134]  S. Siegel,et al.  Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[135]  L. Specht,et al.  FDG-PET in the clinical management of Hodgkin lymphoma. , 2004, Critical reviews in oncology/hematology.

[136]  Roberto Cardarelli,et al.  Meta-analysis: Comparison of F-18 Fluorodeoxyglucose-Positron Emission Tomography and Bone Scintigraphy in the Detection of Bone Metastases in Patients With Breast Cancer , 2008, Clinical nuclear medicine.

[137]  W. Oyen,et al.  The impact of fluor‐18‐deoxyglucose‐positron emission tomography in the management of colorectal liver metastases , 2005, Cancer.

[138]  H. Herschman PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. , 2004, Critical reviews in oncology/hematology.

[139]  N. O’higgins,et al.  Positron emission tomography for staging and management of malignant melanoma , 2002, The British journal of surgery.

[140]  E. Kuipers,et al.  Staging investigations for oesophageal cancer: a meta-analysis , 2008, British Journal of Cancer.

[141]  David W Townsend,et al.  Positron emission tomography/computed tomography. , 2008, Seminars in nuclear medicine.

[142]  W. Oyen,et al.  Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancer , 2007, Cancer.

[143]  Yusuf Menda,et al.  Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. , 2005, Seminars in nuclear medicine.